Almost a year after a licensing dispute between antibody manufacturers Biosite and Xoma turned litigious, the two parties last week announced that they had agreed to resolve their differences out of court. The happy ending to the dispute comes a bit late, however, for Large Scale Biology, which was forced to terminate its business relationship with Biosite for fear of getting caught up in litigation. For now, LSBC officials say it’s too early to comment on whether they’ll consider buying antibodies again from Biosite.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.